Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan G Kermode

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Clinical Immunology (Orlando, Fla.)|January 15, 2016
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapiesFiona C McKay, Prudence N Gatt, Nicole Fewings, et al.
Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2024
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated diseaseGanesha Liyanage, Benjamin P Trewin, Joseph A Lopez, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Response to treatment in NMOSD: the Australasian experienceLaura Clarke, Wajih Bukhari, Cullen M O'Gorman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Clinical Immunology (Orlando, Fla.)|January 15, 2016
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapiesFiona C McKay, Prudence N Gatt, Nicole Fewings, et al.
Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2024
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated diseaseGanesha Liyanage, Benjamin P Trewin, Joseph A Lopez, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Response to treatment in NMOSD: the Australasian experienceLaura Clarke, Wajih Bukhari, Cullen M O'Gorman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.
Pageof 12